Complement pathway modulators and uses thereof

A compound, or salt or a tautomer thereof, according to Formula (I):

• Wherein is a single or double bond;
• X is N or CH;
• Y is N(H), O or S;
• one occurrence of R is cyano and the other occurrence of R is hydrogen or R4;
• R1 is halogen, hydroxyl, C1-C6alkyl, C2-C6alkenyl, C3-C6cycloalkyl, C1-C6alkoxy, haloC1-C6alkyl, hydroxyC1-C6alkyl, aminoC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, C1-C6alkoxyC1-C6alkoxy, C3-C6cycloalkylC1-C6alkoxy, haloC1-C6alkoxy, S(O)pC1-C6alkyl, CH2NHC(O)C1-C4alkyl or OCH2C(O)R7,
• p is 0, 1, or 2;
• R2 is C1-C6alkyl, C1-C6alkoxy, hydroxyC1-C6alkyl or halogen;
• R3 is hydrogen, halogen, cyano, C1-C4alkyl, haloC1-C4alkyl, CH2C(O)R7, phenyl or 5 or 6 member heteroaryl having 1, 2 or 3 ring heteroatoms independently selected from N, O or S, wherein the phenyl or heteroaryl is optionally substituted with 0, 1, or 2 C1-C4alkyl groups, and wherein alkyl and haloalkyl optionally substituted with 0 or 1 hydroxy;
• R4 is 0, 1, or 2 substitutents independently selected at each occurrence from halogen and C1-C6alkyl;
• R5 is hydrogen, C1-C6alkyl, haloC1-C6alkyl, C3-C6cycloalkyl, phenyl or 5 or 6 member heteroaryl having 1, 2 or 3 ring heteroatoms independently selected from N, O or S;
• or R3 and R5 taken in combination form a divalent —CH2—CH2— or —CH2—N(H)— group;
• R6 is hydrogen, hydroxy, amino, C1-C6alkyl, C1-C6alkoxy, C1-C6alkoxyC1-C6alkoxy, mono- and di-C1-C4alkylamino, amino C1-C6alkylamino, [CRA2]nR7, [CRA2]nC(O)R7, O[CRA2]nR7, NHC(O)C1-C6alkyl, NHS(O2)C1-C6alkyl, (CH2)nR9, O(CH2)nR9, C(O)R7, N(H)[CRA2]nR7, O[CRA2]nC(O)R7, N(H)[CRA2]nC(O)R7 or tetrazolyl;
• or CR5R6, taken in combination, form a divalent carbonyl group, a divalent ═CH2 group or cyclopropyl which cyclopropyl is optionally substituted by CO2H or CH2OH;
• n is 1, 2, 3 or 4;
• RA is independently selected at each occurrence from hydrogen, halogen or C1-C4alkyl;
• R7 is hydroxy, C1-C4alkoxy, amino or mono- and di-C1-C4alkylamino R8 is hydrogen or halogen;
• and
• R9 is a 5 member heteroaryl having 1 to 4 ring heteroatoms selected from N, O or S and optionally substituted with 0, 1, or 2 C1-C4alkyl groups.